Diamyd Medical, a company specializing in precision medicine therapies for Type 1 Diabetes, has partnered with the JDRF (Juvenile Diabetes Research Foundation) to revolutionize the treatment of this condition. The partnership aims to develop new strategies for immunomodulatory approaches in Type 1 Diabetes and is focused on Diamyd’s antigen-specific immunotherapy, Diamyd®.
In an upcoming webcast presentation on October 20th, Diamyd Medical’s CEO, Ulf Hannelius, along with Josh Vieth, Director of Research at JDRF, and Mark Atkinson, Director for the University of Florida Diabetes Institute, will discuss the progress and potential of Diamyd® in a Phase 3 trial known as DIAGNODE-3. This antigen-specific immunotherapy is designed to preserve endogenous insulin production in patients with Type 1 Diabetes.
The presentation, hosted by News Agency Direkt and Direkt Studios, will provide an overview of the industry partnership between Diamyd Medical and JDRF, which was first announced in April of this year. The focus will be on the ongoing DIAGNODE-3 trial and the promising results that have been seen so far.
Diamyd Medical’s Diamyd® has shown significant results in previous studies, including a large-scale meta-analysis and the Company’s European Phase IIb trial DIAGNODE-2. In this trial, the immunotherapy was administered directly into a lymph node in children and young adults with recently diagnosed Type 1 Diabetes.
To further support its precision medicine therapies, Diamyd Medical is establishing a biomanufacturing facility in Umeå, Sweden, for the production of recombinant GAD65, the active ingredient in Diamyd®. The company is also involved in the development of Remygen®, a GABA-based investigational drug aimed at regenerating endogenous insulin production.
With its B-share listed on Nasdaq First North Growth Market under the ticker DMYD B, Diamyd Medical continues to pursue innovative solutions for Type 1 Diabetes treatment. The company is also a major shareholder in NextCell Pharma AB, a stem cell company, and MainlyAI AB, an artificial intelligence company.
For further information about Diamyd Medical and its groundbreaking research, interested parties can reach out to their President and CEO, Ulf Hannelius, who can be contacted via phone at +46 736 35 42 41 or by email at ulf.hannelius@diamyd.com.
In conclusion, the partnership between Diamyd Medical and JDRF represents a significant step towards revolutionizing the treatment of Type 1 Diabetes. Through their collaborative efforts, they aim to develop innovative immunomodulatory approaches and advance the antigen-specific immunotherapy, Diamyd®, in order to improve the lives of those affected by this chronic condition.
